The DOI matches its Crossref record; 48 of the 48 references it cites were found in a registry or an index.
Activation of Peroxisome Proliferator–Activated Receptor (PPAR)δ Promotes Reversal of Multiple Metabolic Abnormalities, Reduces Oxidative Stress, and Increases Fatty Acid Oxidation in Moderately Obese Men
Abstract
OBJECTIVE— Pharmacological use of peroxisome proliferator–activated receptor (PPAR)δ agonists and transgenic overexpression of PPARδ in mice suggest amelioration of features of the metabolic syndrome through enhanced fat oxidation in skeletal muscle. We hypothesize a similar mechanism operates in humans. RESEARCH DESIGN AND METHODS— The PPARδ agonist (10 mg o.d. GW501516), a comparator PPARα agonist (20 μg o.d. GW590735), and placebo were given in a double-blind, randomized, three-parallel group, 2-week study to six healthy moderately overweight subjects in each group. Metabolic evaluation was made before and after treatment including liver fat quantification, fasting blood samples, a 6-h meal tolerance test with stable isotope fatty acids, skeletal muscle biopsy for gene expression, and urinary isoprostanes for global oxidative stress. RESULTS— Treatment with GW501516 showed statistically significant reductions in fasting plasma triglycerides (−30%), apolipoprotein B (−26%), LDL cholesterol (−23%), and insulin (−11%), whereas HDL cholesterol was unchanged. A 20% reduction in liver fat content (P < 0.05) and 30% reduction in urinary isoprostanes (P = 0.01) were also observed. Except for a lowering of triglycerides (−30%, P < 0.05), none of these changes were observed in response to GW590735. The relative proportion of exhaled CO2 directly originating from the fat content of the meal was increased (P < 0.05) in response to GW501516, and skeletal muscle expression of carnitine palmitoyl-transferase 1b (CPT1b) was also significantly increased. CONCLUSIONS— The PPARδ agonist GW501516 reverses multiple abnormalities associated with the metabolic syndrome without increasing oxidative stress. The effect is probably caused by increased fat oxidation in skeletal muscle.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Matthews, D. R., Hosker, J. P., Rudenski, A. S., Naylor, B. A., Treacher, D. F., & Turner, R. C. (1985) · Diabetologia · doi:10.1007/bf00280883 · Cited by 31,502
Grundy, S. M., Bilheimer, D. W., Chait, A., Clark, L. T., Denke, M. A., Havel, R. J., Hazzard, W. R., Hulley, S. B., Hunninghake, D. B., Kreisberg, R. A., et al. (1993) · JAMA · doi:10.1001/jama.269.23.3015 · Cited by 27,947
Expert Panel on Detection, E. (2001) · JAMA: The Journal of the American Medical Association · doi:10.1001/jama.285.19.2486 · Cited by 26,011
Yki-Järvinen, H. (2004) · New England Journal of Medicine · doi:10.1056/nejmra041001 · Cited by 1,830
Peroxisome-Proliferator-Activated Receptor δ Activates Fat Metabolism to Prevent Obesity
Wang, Y.-X., Lee, C.-H., Tiep, S., Yu, R. T., Ham, J., Kang, H., & Evans, R. M. (2003) · Cell · doi:10.1016/s0092-8674(03)00269-1 · Cited by 1,296
Regulation of Muscle Fiber Type and Running Endurance by PPARδ
Wang, Y.-X., Zhang, C.-L., Yu, R. T., Cho, H. K., Nelson, M. C., Bayuga-Ocampo, C. R., Ham, J., Kang, H., & Evans, R. M. (2004) · PLoS Biology · doi:10.1371/journal.pbio.0020294 · Cited by 1,089
Oliver, W. R., Shenk, J. L., Snaith, M. R., Russell, C. S., Plunket, K. D., Bodkin, N. L., Lewis, M. C., Winegar, D. A., Sznaidman, M. L., Lambert, M. H., et al. (2001) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.091021198 · Cited by 1,046
Self-citationImprovement in Glucose Tolerance and Insulin Resistance in Obese Subjects Treated with Troglitazone
Nolan, J. J., Ludvik, B., Beerdsen, P., Joyce, M., & Olefsky, J. (1994) · New England Journal of Medicine · doi:10.1056/nejm199411033311803 · Cited by 926
Tanaka, T., Yamamoto, J., Iwasaki, S., Asaba, H., Hamura, H., Ikeda, Y., Watanabe, M., Magoori, K., Ioka, R. X., Tachibana, K., et al. (2003) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0306981100 · Cited by 832
Etiology of Insulin Resistance
Petersen, K. F., & Shulman, G. I. (2006) · The American Journal of Medicine · doi:10.1016/j.amjmed.2006.01.009 · Cited by 825 · cited 1×
“It is thought that such fat accumulation is linked to impaired metabolic function of the tissue in question (5,6).”
BackgroundAdipose tissue as a buffer for daily lipid flux
Frayn, K. (2002) · Diabetologia · doi:10.1007/s00125-002-0873-y · Cited by 752
Self-citationOverproduction of large VLDL particles is driven by increased liver fat content in man
Adiels, M., Taskinen, M.-R., Packard, C., Caslake, M. J., Soro-Paavonen, A., Westerbacka, J., Vehkavaara, S., Häkkinen, A., Olofsson, S.-O., Yki-Järvinen, H., et al. (2006) · Diabetologia · doi:10.1007/s00125-005-0125-z · Cited by 690
Mayerson, A. B., Hundal, R. S., Dufour, S., Lebon, V., Befroy, D., Cline, G. W., Enocksson, S., Inzucchi, S. E., Shulman, G. I., & Petersen, K. F. (2002) · Diabetes · doi:10.2337/diabetes.51.3.797 · Cited by 647
Tiikkainen, M., Häkkinen, A.-M., Korsheninnikova, E., Nyman, T., Mäkimattila, S., & Yki-Järvinen, H. (2004) · Diabetes · doi:10.2337/diabetes.53.8.2169 · Cited by 524
PPARδ regulates glucose metabolism and insulin sensitivity
Lee, C.-H., Olson, P., Hevener, A., Mehl, I., Chong, L.-W., Olefsky, J. M., Gonzalez, F. J., Ham, J., Kang, H., Peters, J. M., et al. (2006) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0511253103 · Cited by 497
Heilbronn, L., Smith, S. R., & Ravussin, E. (2004) · International Journal of Obesity · doi:10.1038/sj.ijo.0802853 · Cited by 412
Staels, B., Vu-Dac, N., Kosykh, V. A., Saladin, R., Fruchart, J. C., Dallongeville, J., & Auwerx, J. (1995) · Journal of Clinical Investigation · doi:10.1172/jci117717 · Cited by 410
Miyazaki, Y., Mahankali, A., Matsuda, M., Glass, L., Mahankali, S., Ferrannini, E., Cusi, K., Mandarino, L. J., & DeFronzo, R. A. (2001) · Diabetes Care · doi:10.2337/diacare.24.4.710 · Cited by 407
Vu-Dac, N., Schoonjans, K., Kosykh, V, Dallongeville, J., Fruchart, J. C., Staels, B., & Auwerx, J. (1995) · Journal of Clinical Investigation · doi:10.1172/jci118118 · Cited by 397
Dressel, U., Allen, T. L., Pippal, J. B., Rohde, P. R., Lau, P., & Muscat, G. E. O. (2003) · Molecular Endocrinology · doi:10.1210/me.2003-0151 · Cited by 372
Bajaj, M., Suraamornkul, S., Pratipanawatr, T., Hardies, L. J., Pratipanawatr, W., Glass, L., Cersosimo, E., Miyazaki, Y., & DeFronzo, R. A. (2003) · Diabetes · doi:10.2337/diabetes.52.6.1364 · Cited by 290
Maggs, D. G., Buchanan, T. A., Burant, C. F., Cline, G., Gumbiner, B., Hsueh, W. A., Inzucchi, S., Kelley, D., Nolan, J., Olefsky, J. M., et al. (1998) · Annals of Internal Medicine · doi:10.7326/0003-4819-128-3-199802010-00002 · Cited by 286
Fat in the liver and insulin resistance
Yki‐Järvinen, H. (2005) · Annals of Medicine · doi:10.1080/07853890510037383 · Cited by 268
Basu, S. (1998) · Prostaglandins, Leukotrienes and Essential Fatty Acids · doi:10.1016/s0952-3278(98)90042-4 · Cited by 254
Self-citationMechanisms of Disease: pathogenesis of nonalcoholic fatty liver disease
Sanyal, A. J. (2005) · Nature Clinical Practice Gastroenterology & Hepatology · doi:10.1038/ncpgasthep0084 · Cited by 216
ReviewIsoprostanes: Novel Bioactive Products of Lipid Peroxidation
Basu, S. (2004) · Free Radical Research · doi:10.1080/10715760310001646895 · Cited by 210
Self-citationSkeletal muscle lipid accumulation in obesity, insulin resistance, and type 2 diabetes
Goodpaster, B. H., & Wolf, D. (2004) · Pediatric Diabetes · doi:10.1111/j.1399-543x.2004.00071.x · Cited by 206
Sprecher, D. L., Massien, C., Pearce, G., Billin, A. N., Perlstein, I., Willson, T. M., Hassall, D. G., Ancellin, N., Patterson, S. D., Lobe, D. C., et al. (2007) · Arteriosclerosis, Thrombosis, and Vascular Biology · doi:10.1161/01.atv.0000252790.70572.0c · Cited by 201
Self-citationvan der Veen, J. N., Kruit, J. K., Havinga, R., Baller, J. F. W., Chimini, G., Lestavel, S., Staels, B., Groot, P. H. E., Groen, A. K., & Kuipers, F. (2005) · Journal of Lipid Research · doi:10.1194/jlr.m400400-jlr200 · Cited by 186
Hällsten, K., Virtanen, K. A., Lönnqvist, F., Sipilä, H., Oksanen, A., Viljanen, T., Rönnemaa, T., Viikari, J., Knuuti, J., & Nuutila, P. (2002) · Diabetes · doi:10.2337/diabetes.51.12.3479 · Cited by 165
Regulation of Dietary Fatty Acid Entrapment in Subcutaneous Adipose Tissue and Skeletal Muscle
Evans, K., Burdge, G. C., Wootton, S. A., Clark, M. L., & Frayn, K. N. (2002) · Diabetes · doi:10.2337/diabetes.51.9.2684 · Cited by 161
Self-citationBasu, S. (1998) · Prostaglandins Leukotrienes and Essential Fatty Acids · doi:10.1016/s0952-3278(98)90070-9 · Cited by 141
Self-citationSierra, M. L., Bénéton, V., Boullay, A.-B., Boyer, T., Brewster, A. G., Donche, F., Forest, M.-C., Fouchet, M.-H., Gellibert, F. J., Grillot, D., et al. (2007) · Journal of Medicinal Chemistry · doi:10.1021/jm058056x · Cited by 123
The effects of rosiglitazone on fatty acid and triglyceride metabolism in type 2 diabetes
Tan, G. D., Fielding, B. A., Currie, J. M., Humphreys, S. M., D�sage, M., Frayn, K. N., Laville, M., Vidal, H., & Karpe, F. (2004) · Diabetologia · doi:10.1007/s00125-004-1619-9 · Cited by 119
Self-citationHaubenwallner, S., Essenburg, A. D., Barnett, B. C., Pape, M. E., Demattos, R. B., Krause, B. R., Minton, L. L., Auerbach, B. J., Newton, R. S., & Leff, T. (1995) · Journal of Lipid Research · doi:10.1016/s0022-2275(20)41090-9 · Cited by 118
Recent advances in the biochemistry and clinical relevance of the isoprostane pathway
Musiek, E. S., Yin, H., Milne, G. L., & Morrow, J. D. (2005) · Lipids · doi:10.1007/s11745-005-1460-7 · Cited by 117
Nikkilä, E. A., Huttunen, J. K., & Ehnholm, C. (1977) · Metabolism · doi:10.1016/0026-0495(77)90053-1 · Cited by 96
Shepherd, J., Packard, C. J., Stewart, J. M., Atmeh, R. F., Clark, R., Boag, D. E., Carr, K., Lorimer, A. R., Ballantyne, D., & Morgan, H. (1984) · Journal of Clinical Investigation · doi:10.1172/jci111643 · Cited by 85
Muscle lipid metabolism in the metabolic syndrome
Perseghin, G. (2005) · Current Opinion in Lipidology · doi:10.1097/01.mol.0000174401.07056.56 · Cited by 50
Sitno, I. E., Yakichuk, J. A., & Ooi, T. C. (1993) · Atherosclerosis · doi:10.1016/0021-9150(93)90067-5 · Cited by 41
Sane, T., Knudsen, P., Vuorinen-Markkola, H., Yki‐Järvinen, H., & Taskinen, M. (1995) · Metabolism · doi:10.1016/0026-0495(95)90115-9 · Cited by 39
Free fatty acid metabolism during fenofibrate treatment of the metabolic syndrome
Vega, G. L., Cater, N. B., Hadizadeh, D. R., Meguro, S., & Grundy, S. M. (2003) · Clinical Pharmacology & Therapeutics · doi:10.1016/s0009-9236(03)00170-x · Cited by 36
Kahri, J., Vuorinen-Markkola, H., Tilly-Kiesi, M., Lahdenperä, S., & Taskinen, M.-R. (1993) · Atherosclerosis · doi:10.1016/0021-9150(93)90086-a · Cited by 34
PPARδ activator GW-501516 has no acute effect on glucose transport in skeletal muscle
Terada, S., Wicke, S., Holloszy, J. O., & Han, D. (2005) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00430.2005 · Cited by 32
Weisweiler, P. (1989) · Metabolism · doi:10.1016/0026-0495(89)90086-3 · Cited by 25
de Man, F. H. A. F., de Beer, F., van der Laarse, A., Jansen, H., Leuven, J. A. G., Souverijn, J. H. M., Vroom, T. F. F. P., Schoormans, S. C. M., Fruchart, J., Havekes, L. M., et al. (2000) · Atherosclerosis · doi:10.1016/s0021-9150(00)00409-3 · Cited by 21
Lambert, D., Catapano, A. L., Smith, L. C., Sparrow, J. T., & Gotto, A. M. (1996) · Atherosclerosis · doi:10.1016/s0021-9150(96)05955-2 · Cited by 17
Cited by
(1998) · PubMed · Cited by 2,737
Myocardial Fatty Acid Metabolism in Health and Disease
Lopaschuk, G. D., Ussher, J. R., Folmes, C. D. L., Jaswal, J. S., & Stanley, W. C. (2010) · Physiological Reviews · doi:10.1152/physrev.00015.2009 · Cited by 2,179
Ratziu, V., Harrison, S. A., Francque, S., Bedossa, P., Lehert, P., Serfaty, L., Romero-Gomez, M., Boursier, J., Abdelmalek, M., Caldwell, S., et al. (2016) · Gastroenterology · doi:10.1053/j.gastro.2016.01.038 · Cited by 1,035
Metabolic requirements for the maintenance of self-renewing stem cells
Ito, K., & Suda, T. (2014) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm3772 · Cited by 1,014
Adiels, M., Olofsson, S.-O., Taskinen, M.-R., & Borén, J. (2008) · Arteriosclerosis, Thrombosis, and Vascular Biology · doi:10.1161/atvbaha.107.160192 · Cited by 820
Metadata
- Authors
- Risérus, U., Sprecher, D., Johnson, T., Olson, E., Hirschberg, S., Liu, A., Fang, Z., Hegde, P., Richards, D., Sarov-Blat, L., Strum, J. C., Basu, S., Cheeseman, J., Fielding, B. A., Humphreys, S. M., Danoff, T., Moore, N. R., Murgatroyd, P., O'Rahilly, S., Sutton, P., Willson, T., Hassall, D., Frayn, K. N., & Karpe, F.
- Venue
- Diabetes
- Publisher
- American Diabetes Association
- Published
- 2008-02-01
- Volume
- 57
- Issue
- 2
- Pages
- 332-339
- ISSN
- 0012-1797 (ISSN-L)
- 1939-327X
- OpenAlex
- W2170075604
- Cited by
- 325
- References
- 48
- FWCI
- 8.74
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.